AI illustration · not actual product photoDetails from the source.
Source-listed SNAP-8 (SKU NP810): 10mg*10vials. PriceList(1).pdf lists 41 per 10 vials but does not specify currency; the website displays $41 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- NP810
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The catalogue lists the exact name SNAP-8. In peer-reviewed cosmetic-peptide literature, SNAP-8 commonly refers to a synthetic acetylated eight-amino-acid peptide, also called acetyl octapeptide-3; published naming is not entirely consistent. The catalogue does not provide a chemical sequence, manufacturer, or formulation, so it is not verified that the NP810 vial is that research ingredient. It is a peptide in that research context, but the vial's identity is unconfirmed.
Biological mechanism
For the research ingredient commonly called SNAP-8, a proposed mechanism is competitive interference with SNAP-25 participation in SNARE-complex assembly, which is involved in vesicle fusion and neurotransmitter release. The mechanism is based on biochemical rationale and nonclinical/computational work; it does not establish a clinical effect or justify equating the peptide with botulinum toxin.
Research focus
Topical cosmetic research has investigated ingredient-identified SNAP-8 in multicomponent formulations for measured facial-line and wrinkle outcomes. Research includes a combination dissolving microneedle patch and a multipeptide skincare serum; neither tests the catalogue vial as supplied.
Potential applications in the evidence
Only cosmetic facial-line/wrinkle appearance has been investigated in the cited human studies, and only as part of multicomponent topical or microneedle formulations. Evidence does not establish a standalone effect, disease treatment, or any application for the exact NP810 vial.
Human evidence
A 2024 comparative study of 24 healthy participants tested a specific dissolving microneedle patch containing acetyl octapeptide-3, hyaluronic acid, L-ascorbic acid 2-glucoside, and sodium cyclic lysophosphatidic acid against an HA placebo for 28 days. Authors reported improvement on some eye-wrinkle/skin measures and no observed adverse effects, but the design cannot isolate the peptide's contribution or establish findings for a different vial or delivery system. A 2016 open-label 14-week study in 29 women evaluated a multi-ingredient peptide serum and skincare regimen that included acetyl octapeptide-3; improvement versus baseline was reported, but no control group and multiple ingredients limit attribution. Human studies have not established efficacy or safety of NP810 itself.
Known and potential effects
The cited studies reported no observed adverse effects for their particular multicomponent topical/microneedle products during the limited study periods. This is not evidence that the isolated ingredient or the listed vial has no adverse effects. A specific adverse-event profile for NP810 cannot be verified.
Safety and contraindications
The catalogue does not specify the vial's contents, excipients, intended use, or route. Consequently, product-specific contraindications and risks cannot be determined. Local irritation or sensitivity cannot be ruled out for an unidentified formulation; small, short, formulation-specific studies cannot characterize rare or delayed harms. The reviewed sources do not establish human safety or efficacy for injection or other non-topical exposure. No contraindication specific to this exact vial was verified.
U.S. FDA / regulatory status
No FDA-approved drug application or FDA-authorized drug formulation for this supplier-specific vial was verified in the reviewed sources. FDA states that cosmetics and cosmetic ingredients generally do not require premarket approval, with an exception for color additives, and explains that intended-use claims may cause a product to be regulated as a drug or both a drug and cosmetic. These general rules do not establish the category or approval status of NP810. Its manufacturer, formulation, jurisdiction, intended use, and approval status cannot be verified; do not infer approval, compounding, or research-only status from the name or catalogue format.
Evidence limitations
The exact vial identity cannot be inferred from the alias SNAP-8. The evidence base includes small studies, limited follow-up, multi-ingredient formulations, differences in delivery method, and nonclinical/mechanistic or manufacturer-reported ingredient data. Standalone efficacy, product-specific safety, vial quality/contents, and regulatory status remain unverified.
Supporting sources
- Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy Frontiers in Chemistry / PubMed Central · Peer-reviewed review. Supports: Common literature identity and proposed SNARE-related mechanism; context that ingredient evidence includes manufacturer-reported/nonclinical material.
- Molecular modeling elucidates the cellular mechanism of synaptotagmin-SNARE inhibition Molecular and Cellular Biochemistry / Springer Nature · Peer-reviewed mechanistic modeling study. Supports: Computational/model-based mechanism discussion; not human efficacy evidence.
- Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities Annals of Dermatology / PubMed Central · Peer-reviewed human clinical study. Supports: Small 2024 human study of a multi-ingredient SNAP-8-containing microneedle patch, reported outcomes, and adverse-event observations.
- An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin Journal of Drugs in Dermatology · Peer-reviewed human clinical study. Supports: 2016 open-label multicomponent serum study, including acetyl octapeptide-3, and limits on attribution.
- Cosmetic Products U.S. Food and Drug Administration · Official regulator guidance. Supports: General U.S. FDA premarket approval rules for cosmetics and responsibility for product safety.
- Cosmetics & U.S. Law U.S. Food and Drug Administration · Official regulator guidance. Supports: U.S. definitions of cosmetics and drugs and role of intended use/claims in regulatory classification.